Trial Profile

A Dose Confirmation Study of FLT180a (Adeno-associated Viral Vector Containing the Padua Variant of a Codon-optimized Human Factor IX Gene) in Adult Subjects With Hemophilia B

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 27 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Verbrinacogene setparvovec (Primary)
Indications Haemophilia B
Focus Adverse reactions; Therapeutic Use
Acronyms B-LIEVE
Sponsors Spur Therapeutics

Most Recent Events

17 Jun 2024 According to Freeline Therapeutics media release, Freeline Therapeutics has changed its name to Spur Therapeutics.
18 Jul 2023 Status changed from active, no longer recruiting to discontinued. Freeline has decided to pause development of FLT180a for business priorities
09 Feb 2023 This trial has been Discontinued in Austria, According to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com